CANCER GENETICS, INC. (NASDAQ:CGIX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
Annual Meeting of Shareholders (the Annual Meeting). The
shareholders of the Company voted on the following two proposals,
each of which is described in detail in the Companys Proxy
Statement on Schedule 14A filed with the Securities and Exchange
Commission on April 21, 2017. The results of each matter voted
upon are as follows:
individuals were elected to the Companys Board of Directors. All
directors of the Company hold office until the next annual
meeting or until their respective successors are duly elected and
qualified or their earlier resignation or removal:
|
Name
|
For
|
Withheld
|
Broker
Non-Votes
|
||||||
|
Panna L. Sharma (President and Chief Executive Officer)
|
6,410,183
|
1,096,200
|
7,625,801
|
||||||
|
John Pappajohn (Chairman of the Board)
|
7,114,743
|
391,640
|
7,625,801
|
||||||
|
Raju S.K. Chaganti, Ph.D.
|
6,347,941
|
1,158,442
|
7,625,801
|
||||||
|
Edmund Cannon
|
7,459,581
|
46,802
|
7,625,801
|
||||||
|
Franklyn G. Prendergast, M.D., Ph.D.
|
7,447,291
|
59,092
|
7,625,801
|
||||||
|
Michael J. Welsh, M.D.
|
6,960,243
|
546,140
|
7,625,801
|
||||||
|
Geoffrey Harris
|
7,459,826
|
46,557
|
7,625,801
|
||||||
|
Howard McLeod
|
7,114,647
|
391,736
|
7,625,801
|
||||||
Accounting Firm.>The shareholders ratified the appointment of
RSM US LLP as our independent registered public accounting firm
for the year ending December 31, 2017.
|
For
|
Against
|
Abstain
|
Broker
Non-Votes
|
|||
|
14,263,452
|
813,627
|
55,105
|
About CANCER GENETICS, INC. (NASDAQ:CGIX)
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.
